© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#IAS 2019
Click Here for More Conferences
Click Here for IAS Online
HIV: The Basics

Fostemsavir Can Best Drug-Resistant HIV

The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.

Extensive Drug Resistance Has Become Rare Among People With HIV

Researchers attribute the decline in multidrug-resistant virus, which began in 2004, to newer, highly potent antiretrovirals.

The International AIDS Society Conference’s Most Vital Findings

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Aerobic Exercise Tied to Improved Depression in People With HIV

However, a recent literature review did not find a link between such exercise and improved inflammation.

Blood Tests Can Predict Fatty Liver Disease in Those With HIV

Researchers have identified biomarkers that can identify NAFLD and rule out advanced fibrosis.

HIV Test-and-Treat Program Would Greatly Lower HIV in Africa

The PopART study is one of three that have recently reported findings of such programs in sub-Saharan Africa.

Only Subnormal Kidney Function May Get Boost From Switch to New Tenofovir

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

2-Drug Regimen Is Comparably Effective to 3-Drug Treatment

Updating previous, similar findings, researchers have now reported on 96-week data from a pair of ongoing trials.

High HIV Suppression Among Those Who Switch to Two-Drug Dovato

A late-stage trial randomized people taking a stable HIV regimen to switch to Dovato or stay on their current antiretrovirals.
Rebecca Zash at IAS 2019 press briefing

Dolutegravir Associated With Low Risk of Neural Tube Birth Defects

The World Health Organization recommends this highly effective antiretroviral for all population groups, including young women.
S Amele et al, IAS 2019, abstract WEAB0303

Hep C Reinfection Rate Reaches 13% for HIV-Positive People Cured in Europe

Large European study finds that more than 1 in 10 people with HIV acquire HCV again.

WHO Endorses On-Demand PrEP for Gay and Bi Men

On-demand, or 2-1-1, PrEP requires taking only four doses of Truvada during the days surrounding sex.

Statins Did Not Slow Plaque Buildup in Arteries in People With HIV

A recent study randomized those with a moderate long-term risk of heart attack to receive Crestor (rosuvastatin) or a placebo.

Providing Same-Day PrEP Is Feasible in Latin America

Researchers provided an initial Truvada prescription to eligible gay and bi men and trans women at their first appointment.

In San Francisco, Stopping PrEP Is Linked to 8-Fold Increase in HIV Rate

Nationwide, significant proportions of PrEP-using populations do not stay on Truvada for long.

High Satisfaction Among Users of Monthly Injectable HIV Treatment

The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Advertisement
Newsfeed
Treatment News